The Multiple Myeloma Channel is supported with funding from AbbVie (Platinum), Sanofi (Gold), Legend Biotech (Bronze), and through an educational grant from Alexion Pharma GmbH.
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
iwHRMM 2026 | Integrating MRD and genomic profiling to guide treatment in high-risk myeloma
Benjamin Diamond, MD, Sylvester Comprehensive Cancer Center, Miami, FL, discusses the potential of integrating measurable residual disease (MRD) assessment and genomic profiling to guide treatment decisions in high-risk multiple myeloma. He highlights the MASTER (NCT03224507) and MIDAS (NCT04934475) trials and explores how incorporating whole-genome sequencing into MRD-guided strategies could improve risk assessment and support more personalized treatment approaches. This interview took place at the 3rd International Workshop on High-Risk Multiple Myeloma (iwHRMM 2026), held in Charleston, SC.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
